Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
Welslau, Manfred, Diéras, Veronique, Sohn, Joo-Hyuk, Hurvitz, Sara A., Lalla, Deepa, Fang, Liang, Althaus, Betsy, Guardino, Ellie, Miles, DavidVolume:
120
Language:
english
Journal:
Cancer
DOI:
10.1002/cncr.28465
Date:
March, 2014
File:
PDF, 575 KB
english, 2014